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Abstract
Background—Ambulatory blood pressure (ABP) is consistently superior to clinic blood 
pressure (CBP) as a predictor of cardiovascular morbidity and mortality risk. A common 
perception is that ABP is usually lower than CBP. The relationship of the CBP minus ABP 
difference to age has not been examined in the United States.
Methods—Between 2005 and 2012, 888 healthy, employed, middle-aged (mean ± SD: 45 ± 10.4 
years) individuals (59% female, 7.4% African-American, 12% Hispanic) with screening BP 
<160/105 mmHg and not taking antihypertensive medication completed three separate clinic BP 
assessments and a 24-hour ABP recording for the Masked Hypertension Study. The distributions 
of CBP, mean awake ABP (aABP), and the CBP-aABP difference in the full sample, and by 
demographic characteristics were compared. Locally weighted scatterplot smoothing (LOESS) 
was used to model the relationship of the BP measures to age and BMI. The prevalence of 
discrepancies in ABP- vs CBP-defined hypertension status – white-coat hypertension and masked 
hypertension – were also examined.
Results—Average awake systolic/diastolic ABP (123.0/77.4 ± 10.3/7.4 mmHg) was significantly 
higher than the average of 9 CBP readings over 3 visits (116.0/75.4 ± 11.6/7.7 mmHg). aABP 
exceeded CBP by more than 10 mmHg much more frequently than CBP exceeded aABP. The 
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difference (aABP>CBP) was most pronounced in young adults and those with normal body mass 
index (BMI). The systolic difference progressively diminished, though did not disappear, at older 
ages and higher BMIs. The diastolic difference vanished around age 65, and reversed 
(CBP>aABP) for BMI>32.5 kg/m2. While 5.3% of participants were hypertensive by CBP, 19.2% 
were hypertensive by aABP; 15.7% of those with non-elevated CBP had masked hypertension.
Conclusions—Contrary to a widely held belief, based primarily on cohort studies of patients 
with elevated CBP, ABP is not usually lower than CBP, at least not among healthy, employed 
individuals. Furthermore, a substantial proportion of otherwise healthy individuals with non-
elevated CBP have masked hypertension. Demonstrated CBP-aABP gradients, if confirmed in 
representative samples (e.g., NHANES), could provide guidance for primary care physicians as to 
when, for a given CBP, 24-hr ABP would be useful to identify or rule out masked hypertension.
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Introduction
The era of 24-hour ambulatory blood pressure monitoring (ABPM) was ushered in with 
Perloff and Sokolow’s seminal 1983 article on the prognostic value of ABP.1 During the 
subsequent 30 plus years, ABPM has been assessed in numerous clinical and population 
cohorts. The most profound and replicable finding from these studies continues to be the 
superiority of ABP, compared to clinic blood pressure (CBP), as a correlate of target organ 
damage and a predictor of cardiovascular (CV) morbidity and mortality risk (see systematic 
reviews,2, 3 summarized in Siu4). The explanation of this finding remains unclear.
The use of ABPM also led to the identification of white-coat hypertension – where the CBP 
is elevated but the average awake ABP (aABP) is not elevated – in cohorts of clinic 
patients.5 This, in turn, led to interest in the difference between CBP and aABP, often 
referred to as the “white-coat effect”. Data from numerous cohorts of mostly older patients 
with hypertension or suspected hypertension showed that CBP was consistently greater than 
aABP, often by more than 10 mmHg,6, 7 leading to the commonly held perception, as 
codified in the JNC 7, that “[A]mbulatory BP values are usually lower than clinic readings 
(Chobanian et al, p 1214, emphasis added).”8
When the CBP-ABP difference was subsequently examined in population and community-
based samples with a broad age range, all from Europe, Japan, China and South America, a 
different picture emerged. After excluding individuals with a history of cardiovascular 
disease (CVD) and those taking an antihypertensive medication, the average CBP for the full 
sample was consistently lower than the average aABP. Further analyses,9–12 broken down by 
10-year age cohorts, showed that the CBP-aABP difference was most negative in the 
youngest cohorts (aABP higher than CBP) and most positive in the oldest cohorts (CBP 
higher than aABP). This was confirmed in a meta-analysis of 27 studies and a recent 
analysis of 9550 untreated individuals.13, 14 However, the relationship between age and the 
CBP-aABP difference has not been examined in the United States. This paper extends our 
understanding of the CBP-aABP difference by, 1) examining for the first time data from a 
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large-scale, healthy, community sample in the United States, and 2) extending the search for 
correlates of this difference to other demographic factors and body mass index.
Methods
The Masked Hypertension Study is a multi-site study conducted at Stony Brook University 
and Columbia University. Between 2005 and 2012, 1011 employees of these two 
universities, their medical schools and affiliated hospitals, and a private hedge fund 
management organization enrolled in the study. The study adhered to the guidelines set forth 
by the Declaration of Helsinki and was approved by the institutional review boards of Stony 
Brook University and Columbia University Medical Center.
Inclusion/exclusion criteria
Recruitment was restricted to employees aged 21 and over who worked ≥17.5 hours/week, 
spoke and read English, had a pre-enrollment screening blood pressure of <160/105 mmHg, 
and were not taking a blood pressure lowering medication. Individuals with evidence of 
secondary hypertension, a history of overt CVD (myocardial infarction, stroke, percutaneous 
transluminal coronary angioplasty), or chronic renal, liver, thyroid, or adrenal disease were 
ineligible, as were those with cancer not in remission for at least 6 months, active substance 
abuse or a serious mental health illness. Those taking any cardiovascular medication (other 
than a statin) and women who were pregnant were also ineligible. Diabetes was not an 
exclusion criterion.
Protocol
Recruitment took place on a department by department basis within each organization. With 
the permission and support of the department head, on-site “public health blood pressure 
screenings” were conducted by study personnel. All employees were invited to have their BP 
taken (3 readings taken in accordance with the American Heart Association guidelines). 
During the 2-minute intervals between readings, the study was briefly described, 
highlighting the findings that ABP can differ substantially from CBP and that ABP is a 
better predictor than CBP of CV risk. Those with a screening BP (mean of second and third 
readings) that was <160/105 mmHg who were not taking blood pressure lowering 
medication and had no history of overt CVD (e.g., myocardial infarction, cardiac/coronary 
surgery, stroke) were invited to provide their name and contact information for future 
recruitment. (Blood pressure screenings were not conducted at the hedge fund management 
firm. Instead, a public presentation about the study was made to all employees and those 
interested in potentially participating provided contact information. Eligibility was 
confirmed during the phone screen, and the BP screening criterion was confirmed at the 
beginning of Visit 1.) Individuals who provided this information were subsequently 
contacted by phone, at which time the study protocol was described in detail and full 
eligibility was ascertained. Those who agreed to participate were then scheduled for the first 
of 5 study visits (see Figure 1) and mailed the study’s informed consent document to review.
At Visit 1, individuals provided signed informed consent and then had their CBP taken by a 
trained technician using a mercury column sphygmomanometer (Baum; Copiague, NY) and 
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stethoscope. The technician confirmed that the participant had not smoked, eaten, or had a 
caffeinated beverage during the prior 30 minutes and then measured the arm circumference 
of the non-dominant arm. After being seated comfortably for a minimum of 5 minutes, the 
participant was asked to remain still, feet flat on the floor and back supported, and to not talk 
while 3 BP readings were taken at 1–2 minute intervals on the non-dominant arm using an 
appropriate-sized BP cuff. The participant was given an extensive psychosocial 
questionnaire to complete at home, and asked to return it by Visit 3.
Visit 2 was scheduled for 1 week later (on a different day of the week and time of day), 
when the same protocol was used to measure CBP. Visit 3 was scheduled another week later 
and began with CBP being assessed for the third and final time. The participant was then 
fitted with a 24-hour ABPM (SpaceLabs 90207, Snoqualamie, WA), a waist actigraphy 
device (Actical, Philips Respironics, Bend, OR) to assess physical activity, a wrist 
actigraphy device (ActiWatch, Philips Respironics, Bend, OR) to assess sleep onset/offset 
and sleep duration, and provided a pre-programmed electronic diary (Palm Pilot Tungsten 3) 
on which they were asked to answer questions after each BP reading regarding their 
situation, activities, affect and social interactions immediately prior to the reading. 
Participants wore the equipment for 24 hours, returning it the next day (Visit 4). At this time, 
they were scheduled for Visit 5.
During Visit 5, a comprehensive medical history, including family history of major 
disorders, was obtained by interview. Participants were also interviewed about their smoking 
history, and completed a health activities questionnaire and health-related quality of life 
questionnaire (SF-36).15 Height and weight (no shoes, light clothing) and skinfolds were 
measured. Fasting blood sample was obtained and urinary albumin and creatinine were 
measured from a complete overnight urine collection (all voids after going to sleep and first 
morning void after awakening). A 12-lead electrocardiogram was obtained and a research 
2D echocardiogram was performed. Visits 1–4 always took place on a workday, and all 
visits were conducted at either the hospital clinical research center (CRC) or our lab’s 
clinical offices.
Blood pressure measures
The average of the participant’s 3 blood pressure readings taken at Visit 1 is comparable to 
the assessment of CBP in most epidemiological studies. The average of the 9 readings from 
Visits 1–3 provides a more robust measure of CBP, and is the measure used in most of our 
analyses. For comparability with prior studies, some results are also presented for the Visit 1 
CBP measure.
The ABP monitor was programmed to take readings at 28-minute intervals and participants 
were told that readings would be taken “every 25–30 minutes”. While it is more typical to 
use 15-, 20-, or 30-minute intervals, 28 minutes was deliberately chosen to ensure that 
readings were not taken at the same time each hour, thereby reducing participants’ ability to 
anticipate when the next reading would occur. Based on the manufacturer’s 
recommendation, systolic BP readings outside the range of 70 mmHg (60 mmHg during 
sleep) to 250 mmHg, and diastolic readings outside the range of 40 mmHg (30 mmHg 
during sleep) to 150 mmHg were treated as errors. Participants completed a device log, 
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recording the times that they went to sleep, woke up, took a nap, and/or removed any of the 
equipment (e.g., to exercise or shower). The Actiware software (Philips Respironics) was 
used to analyze the Actiwatch recording and, in conjunction with the self-report times, arrive 
at a best estimate of sleep onset and awakening. Based on these times, the average awake 
and average sleep ambulatory BP were computed. Consistent with the International 
Database on ABPM in relation to Cardiovascular Outcomes (IDACO),16 a minimum of 10 
valid readings was required to compute the average aABP and a minimum of 5 valid sleep 
readings was required to compute the average sleep (nighttime) ABP. Of the 893 participants 
who were fitted with an ABPM device, only 5 had fewer than 10 valid awake readings, 
leaving a final sample size of 888 participants for analysis. They had an average of 44.3 
valid readings (SD: ±7.6; range: 10 – 60) and 93.1% (±8.0) of attempted BP readings were 
successful on either the first try or the automatic re-try 2 minutes later; the average number 
of valid awake readings was 32.1 (±5.0; range 10 – 43). Seventy-five participants did not 
wear the device to bed and another 41 had fewer than 5 valid sleep readings; the remaining 
772 participants had an average of 13.5 (±3.1; range 5 – 21) valid sleep readings.
Hypertension categories (BP phenotypes)
Those with a systolic CBP ≥140 mmHg and/or diastolic CBP ≥90 mmHg were classified as 
having clinic-based hypertension; those with systolic CBP <140 mmHg and diastolic CBP 
<90 mmHg were classified as having non-elevated CBP or normotension. The corresponding 
systolic/diastolic aABP thresholds used for the diagnosis of ABP-defined hypertension are 
135/85 mmHg.8, 17, 18 Those with elevated CBP and non-elevated aABP were classified as 
having white-coat hypertension; those with non-elevated CBP and elevated aABP were 
classified as having masked hypertension; those whose CBP and aABP were either both 
elevated or both non-elevated were classified, respectively, as having sustained hypertension 
or sustained normotension.
Statistical Analysis
The CBP-aABP difference, and how it varies in relationship to other factors, cannot be 
understood without also examining CBP and aABP separately. Accordingly, we describe and 
compare the distributions of each – CBP, aABP, and the CBP-aABP difference – in the 
sample as a whole, and by demographic characteristics. T-tests and analysis of variance are 
used to test for group differences in means; paired t-tests are used to compare CBP and 
aABP in the same participant for the full sample and within subgroups. Locally weighted 
scatterplot smoothing (LOESS) with iterative reweighting is used to model the relationship 
of the BP measures to age and BMI. The prevalence of each blood pressure phenotype 
(sustained normotension, white-coat hypertension, masked hypertension, and sustained 
hypertension) is calculated. Finally, a LOESS logistic model summarizing how the 
probability of an elevated systolic aABP (i.e., ≥135 mmHg) varies in relationship to the 
systolic CBP is estimated in the subsample of those with non-elevated CBP; the same is 
done for diastolic BP. Following multiple imputation for missing Visit 5 data using the “fully 
conditional specification” approach,19 multivariable regression models predicting the CBP-
aABP difference in the full sample and logistic regression models predicting elevated aSBP, 
elevated aDBP, and masked hypertension status in those with non-elevated CBP were 
estimated. ANCOVA was used to examine differences among BP phenotypes in echo-
Schwartz et al. Page 5





















defined left ventricular mass index (LVMI, calculated according to the standard ASE 
formula,20 indexed by estimated body surface error) and overnight urinary albumin-
creatinine ratio. A 2-tailed p-value of 0.05 is used to judge statistical significance. All 
analyses were performed using SAS, version 9.4 (SAS Institute Inc, Cary, NC).
Results
Approximately 2600 employees participated in the on-site BP screenings (see Figure 2). Of 
these, 1931 appeared potentially eligible, of whom 89.1% provided contact information. 
Phone screens were conducted with 1699 individuals (including 54 from the financial 
organization where BP screenings were not conducted), and 1254 met all eligibility criteria. 
A total of 1011 individuals (80.6% of those who were eligible) enrolled in the study and 
completed Visit 1; 904 (89.4%) had CBP assessed on three separate occasions (Visits 1, 2, 
and 3); 893 wore the ABPM (888 had 10 or more valid awake readings; 773 had 5 or more 
valid sleep readings); and 842 (83.3%) completed the cardiovascular evaluation (Visit 5).
The sample is middle-aged (mean 45.0 years, SD= 10.4), 59% female, 7.4% Black/African-
American and 12% Hispanic, with an average BMI of 27.6 (5.3) kg/m2. In the medical 
history interview, 3.6% reported having diabetes (see Table 1). Supplemental Table 1 
compares the 888 participants with a valid ABPM recording to the 123 who enrolled in the 
study but withdrew prior to completing the ABPM (n=118) or had fewer than 10 valid awake 
ABP readings (n=5). While those who withdrew were younger and more likely to be Black 
and/or Hispanic, there were no differences in sex or CBP.
The mean (SD) of the Visit 1 systolic/diastolic CBP (average of 3 readings) was 116.1/76.0 
(12.9/8.9) mmHg, while the mean pooled across all 3 visits (9 readings in total), was 
116.0/75.4 (11.6/7.7) mmHg. The mean (SD) of the average awake and average sleep ABPs 
were 123.0/77.4 (10.3/7.4) mmHg and 106.2/61.9 (10.5/7.7) mmHg, respectively. The 
histograms shown in Figure 3 illustrate how the entire distribution of aABP is shifted 
upward, especially for systolic BP (Panel A), relative to that for CBP (mean of 3 visits). 
Systolic and diastolic aABP were 7.0 (8.0) and 2.0 (6.5) mmHg higher than CBP (both 
p<0.0001 by paired t-test). Panels C and D show that CBP minus aABP is approximately 
normally distributed for both systolic and diastolic BP. Supplemental Figure 1 contains 
Bland-Altman plots for systolic and diastolic BP showing that, a) the CBP-aABP difference 
is relatively uncorrelated with the average, and b) the variance of the difference is fairly 
homogeneous across levels of BP. Table 2 summarizes information about the distribution of 
difference scores. More than one-third of participants had a systolic aABP that exceeded 
their CBP by at least 10 mmHg, while only 2.5% had a systolic CBP that exceeded their 
aABP by this much, a ratio of nearly 14:1. For diastolic BP, more than twice as many 
participants had an aABP that exceeded their CBP by at least 5 mmHg (32.4%) as had a 
CBP that exceeded their aABP by this amount (14.2%). Supplemental Table 2 provides the 
correlations among CBP readings at each visit, the 3-visit average, and the mean awake and 
sleep ABP.
We next examine how CBP, aABP, and the CBP-aABP difference vary by sex, race, 
ethnicity, and BMI. As expected, males had higher BP (both CBP and aABP) than females, 
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Blacks had higher BP than non-Blacks (though the differences were not statistically 
significant due to the relatively small number of Black participants), and those who were 
overweight or obese had higher BP than those with a normal BMI (see Table 3). Hispanics 
tended to have lower systolic BP than non-Hispanics, but the difference was only 
statistically significant for systolic aABP. While the subgroup differences in CBP were 
somewhat larger than in aABP, the CBP-aABP difference did not significantly differ by sex, 
race, or ethnicity; there was, however, a tendency for the diastolic CBP-aABP difference to 
be more negative (i.e., aABP greater than CBP) for females than males (p=0.051). (Smoking 
status [never, past, current] was not significantly associated with systolic or diastolic CBP, 
aABP, or the CBP-aABP difference; results not shown.) In contrast, the CBP-aABP 
difference varied considerably with BMI. It was most negative for the normal BMI group 
and smallest for the obese group; the difference in diastolic BP was slightly positive in the 
obese group.
It is generally recognized that one factor contributing to the finding that ABP is a superior 
predictor of adverse CV events, compared to CBP, is that many studies only assessed CBP at 
a single visit. Averaging CBP across multiple visits increases the reliability of the measure 
by reducing the impact of visit-to-visit variability. This increased reliability is, in turn, 
expected to result in statistically stronger associations between CBP and other measures 
(predictors/correlates of CBP, ABP, and outcomes). This expectation is born out in Table 3, 
where a comparison of the t- and F-statistics for the two versions of CBP demonstrates that 
the associations of demographic factors and BMI with CBP were stronger when CBP was 
measured as the average across 3 visits (9 readings) instead of just 1 visit (3 readings). 
Similarly, Supplemental Table 2 shows that the correlations of CBP with aABP and mean 
sleep ABP were higher for the 3-visit average CBP than for the single visit CBP measures.
LOESS models were used to examine the relationship of CBP, aABP, and the CBP-aABP 
difference with age and BMI, treated continuously. As shown in Figure 4 (Panel A), the age 
gradients of systolic aABP and CBP were non-linear, becoming steeper at higher ages. The 
difference (CBP being lower than aABP) was greatest for those who were young, but the age 
gradient of CBP was steeper than that of aABP, especially after age 50, resulting in a 
steadily decreasing difference at older ages. In this study, the systolic CBP-aABP difference 
was significantly less than zero (i.e., aABP > CBP) for all ages between 21 and 70 years. 
Panel B contains the corresponding results for diastolic BP. It shows the curvilinear 
relationships of diastolic CBP and aABP with age, with the gradient being steeper for CBP 
than aABP after about age 45; the diastolic aABP was significantly higher than diastolic 
CBP for all ages below 60. LOESS models of the systolic and diastolic CBP-aABP 
differences in relation to age appear in Supplemental Figure 2 (Panels A and B).
Figure 4 also shows the relationships of CBP and aABP to BMI (Panels C and D). Systolic 
and diastolic aABP were substantially higher than CBP for BMI levels below 25 kg/m2; the 
differences in systolic BP diminished at increasing levels of BMI, but remained statistically 
significant up to about 43 kg/m2; however, the diastolic CBP-aABP difference became 
positive for BMI values of 32.5 kg/m2 and above, and this difference was statistically 
significant for BMI levels above 35 kg/m2. Again, the LOESS models for the CBP-aABP 
difference appear in Supplemental Figure 2 (Panels C and D).
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In multivariable regression models, age and BMI continue to be significantly associated with 
the CBP-aABP difference in both systolic and diastolic BP. After taking the square root of 
BMI, its relationship to the CBP-aABP is approximately linear for both BP measures. The 
relationship of age to the CBP-aABP differences in systolic and diastolic BP is significantly 
different for men and women. Supplemental Table 3 shows estimates for models that include 
all predictors (full model), and for parsimonious models where non-significant factors 
(p≥0.10) have been removed. Supplemental Figure 3 portrays the relationship of age to the 
systolic and diastolic CBP-aABP differences for men and women. As in the bivariate 
analyses, Black race and smoking status were not associated with the systolic and diastolic 
CBP-aABP differences; Hispanic ethnicity was marginally associated with the systolic CBP-
aABP difference (p=0.09, with the difference being 1.35 mmHg less negative for Hispanics) 
only.
Diagnostic Categories (BP phenotypes)
In this sample of individuals who were free of CVD, did not screen positive for Stage 2 
hypertension, and were not taking any blood pressure lowering medication, 5.3% of the 
sample were hypertensive by CBP (i.e., ≥140/90 mmHg, based on the average of 9 readings 
across 3 visits), whereas 19.1% were hypertensive by aABP (i.e., ≥135/85 mmHg). The 
prevalences of sustained normotension, masked hypertension, white-coat hypertension and 
sustained hypertension were 79.8%, 14.9%, 1.0% and 4.3%, respectively. Although 84.1% 
had the same diagnosis by aABP as by CBP, the kappa statistic was only 0.29 (95% CI: 0.21 
to 0.37) indicating only poor or fair agreement between the two diagnoses.21, 22 Of 
particular interest, 132 (15.7%) of the 841 participants who were normotensive based on 
their CBP had masked hypertension (aABP ≥135/85 mmHg); 9 (19.1%) of the 47 
participants who were hypertensive by CBP had white-coat hypertension (aABP <135/85 
mmHg). Of those with masked hypertension, 49 had both elevated systolic and elevated 
diastolic aABP, whereas 55 had only elevated diastolic aABP, and 28 had only elevated 
systolic aABP.
The probability of having masked hypertension is not the same for all individuals with non-
elevated clinic BP. Figure 5 presents plots, based on LOESS logistic analyses of the 841 
whose systolic and diastolic CBP were both non-elevated, showing the predicted likelihood 
of an elevated systolic (Panel A) or diastolic (Panel B) aABP for individuals with different 
values of CBP. It shows, for example, that 10% of those whose average systolic CBP over 3 
visits was 120 mmHg were expected to have a systolic aABP ≥135 mmHg; this increased to 
34% for those with a systolic CBP of 130 mmHg and exceeded 50% for those with a systolic 
CBP of 135 mmHg or greater. Similarly, 20% of those whose average diastolic CBP over 3 
visits was 80 mmHg were expected to have a diastolic aABP ≥85 mmHg, and this increased 
to over 50% for those whose diastolic CBP was 87 mmHg or greater. Tables 4 and 5 show 
the observed probability of having masked hypertension for different combinations of 
systolic and diastolic CBP, depending on whether CBP is based on a single visit (Table 4) or 
three visits (Table 5).
Males with non-elevated clinic BP were more likely than females to have systolic aABP 
≥135, diastolic aABP ≥85 mmHg, and masked hypertension (all p<0.0001); Black race, 
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ethnicity, and smoking status were not significantly associated (all p>0.10). BMI was 
positively associated with systolic aABP ≥135 (p<0.0001), and masked hypertension 
(p<0.002), but not diastolic aABP ≥85 mmHg (p=0.35). Age was positively associated with 
systolic aABP ≥135 (p<0.0001), with no difference between males and females; it was 
positively associated with diastolic aABP ≥85 mmHg and masked hypertension for males 
(p=0.004 and p<0.0001), but curvilinearly (inverse U-shape) related for females (p=0.02, 
and p=0.04).
Clinic BP is overwhelmingly the strongest predictor of who will have elevated aABP and 
masked hypertension. After controlling for the relationship of clinic systolic BP with 
systolic aABP ≥135, there was a significant sex*age interaction such that age was 
independently related to elevated systolic aABP for males only (p=0.009); BMI was no 
longer associated (see Supplemental Table 4). After controlling for the relationship of clinic 
diastolic BP to diastolic aABP ≥85 mmHg, clinic systolic BP (p=0.02) was positively 
associated and BMI (p=0.002) was negatively associated; there was a significant sex*age 
interaction (p=0.008) such that with increasing age, women were less likely (p=0.02) and 
men were marginally more likely (p=0.07) to have elevated diastolic aABP. Both systolic 
and diastolic CBP were strong predictors of masked hypertension (both p<0.0001). 
Controlling for these, there was again a significant sex*age interaction (p=0.003) such that 
with increasing age, women were marginally less likely (p=0.06) and men were substantially 
more likely (p=0.006) to have masked hypertension (Supplemental Figure 4).
Associations of BP Phenotypes with Target Organ Damage
The average left ventricular mass index (LVMI) among those with masked hypertension was 
significantly higher than among sustained normotensives, but significantly lower than those 
with sustained hypertension (Supplemental Table 5). There were no significant differences in 
log-transformed urinary albumin-creatinine ratio among the BP phenotypes (p=0.64).
Discussion
In this relatively large U.S. sample of employed adults free of CVD, who had a pre-
enrollment screening BP <160/105 mmHg, and were not taking an antihypertensive 
medication, ABP was not usually lower than CBP. We found that, on average, systolic aABP 
was 7 mmHg higher than CBP, and diastolic aABP was 2 mmHg higher. Examination of the 
distribution of the difference between CBP and aABP revealed that aABP exceeded CBP by 
10 mmHg or more in nearly 35% of participants and 9% had a comparably large diastolic 
difference; in contrast, CBP exceeded aABP by this amount in only 2.5% (systolic) and 
4.2% (diastolic) of participants. Thus, while the view that ABP is usually lower than clinic 
BP may well hold for older individuals with elevated CBP,8 especially those being treated 
for hypertension and those wearing an ABPM to rule-out white-coat hypertension, it is not 
true in this sample or, we suspect, in the general U.S. adult population.
This study confirms findings from non-U.S. population/community studies that the CBP-
aABP difference varies systematically with age.9, 12 The difference, with aABP being higher 
than CBP, is most pronounced in young adults and progressively diminishes at older ages. 
However, unlike most prior studies, where the difference crossed zero and CBP began to 
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exceed aABP somewhere between the age of 50 and 60, this never happened for systolic BP 
and only happened for diastolic BP in those above the normal retirement age. Importantly, 
the number of individuals above the age of 65 in our sample was small and, by design, all 
were employed. Further research is needed to determine whether this pattern would hold in 
other samples of employed individuals (e.g., in other types of occupations and organizations, 
or outside the New York metropolitan area) or in a representative sample of employed, non-
employed and retired individuals. The inclusion of ABPM in the U.S. National Health and 
Nutrition Examination Survey (NHANES) would allow these and other questions to be 
addressed.
This is one of only a handful of studies to compare the BMI gradients for CBP and aABP. 
The CBP-aABP difference was greatest, with aABP being higher than CBP, for those with 
low BMI and became progressively smaller at increasing levels of BMI. For systolic BP, 
there was no level of BMI at which CBP exceeded aABP whereas for diastolic BP, CBP 
began to exceed aABP at 32.5 kg/m2, and became significantly greater at a BMI of about 35 
kg/m2. The CBP-aABP difference was similar for men vs. women, Blacks vs. non-Blacks, 
Hispanics vs. non-Hispanics, and cigarette smokers vs. past smokers vs. never smokers.
One plausible explanation for the finding that the age and BMI gradients of aABP are less 
steep than the corresponding gradients for CBP is that younger individuals and those with 
lower BMI are more physically active, raising their aABP substantially above their resting 
BP. In essence, physical activity might be suppressing the associations of aABP with age and 
BMI. This potential suppressor effect of physical activity on the relationship of ABP to age 
and BMI is an important topic for future research, which we hope to address in a future 
analysis of the actigraphy data collected in this study.
Multivariate regression analyses confirmed the independent associations of age and BMI 
with the systolic and diastolic CBP-aABP difference. They also revealed that the 
relationship of age to the difference is different for men and women.
Ideally, primary care physicians will find the results presented here useful when evaluating 
the BP of a patient during a well-care visit/physical exam. The physician’s dilemma is that 
s/he only knows the patient’s CBP, but it is the ABP that is most prognostic. Knowing that if 
the patient is young and/or has a low BMI, his/her ABP is likely to be considerably higher 
than the CBP could inform the decision of whether to recommend a 24-hour ABPM. On the 
other hand, if the patient is 60 years old and mildly obese, then the CBP may be relatively 
unbiased.
Only 5% of our sample met criteria for hypertension based on CBP, whereas 19% had 
hypertension based on their aABP. Furthermore, only 1% met criteria for white-coat 
hypertension, while 14.9% met criteria for masked hypertension. While the goal of the 
U.K.’s 2011 NICE guideline and the recent United States Preventive Services Task Force 
(USPSTF) recommendation that ABPM be performed in those with elevated clinic BP in 
order to rule-out white-coat hypertension and reduce unnecessary treatment is laudable and 
apparently cost-effective,4, 23 the current study points to the potential utility of ABPM for 
identifying the sizeable number of individuals with masked hypertension who are 
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normotensive in the clinic setting but have average daytime blood pressures that exceed the 
threshold for hypertension. Prior research has shown that these individuals have target organ 
damage and are at risk for future adverse CV events at rates that exceed those with sustained 
normotension (i.e., non-elevated CBP and non-elevated aABP) and are similar to those with 
sustained hypertension,24–27 and this is supported by recent findings from the U.S. Dallas 
Heart Study (using home BP monitoring) and Jackson Heart Study.28, 29 In the present study, 
the average LVMI of those with masked hypertension exceeded that for sustained 
normotensives, but was lower than for sustained hypertensives. Although there is a prima 
facie case for initiating life style changes and/or blood pressure lowering medication in 
individuals with masked hypertension, there is, in our opinion, an urgent need for 
randomized clinical trials testing the effect of potential interventions on CV risk in this 
population.
Individuals with low CBPs are unlikely to have masked hypertension, since this would 
require a very large difference between CBP and aABP, for aABP to reach the ambulatory 
hypertension threshold. As the CBP increases, it becomes increasing likely that the aABP 
will exceed the threshold for hypertension. This pattern probably explains much of the 
variability in previously published prevalence estimates of masked hypertension. For 
example, Viera and colleagues reported a prevalence of 43%, but their sample was restricted 
to individuals who screened positive for pre-hypertension and had a study CBP ≥110/70 
mmHg;30 this excludes those with the lowest probability of having masked hypertension and 
results in a prevalence estimate that is considerably higher than that of the general 
population with non-elevated CBP. Again, inclusion of ABPM in the NHANES would yield 
a definitive estimate of the masked hypertension prevalence in the U.S. general population.
Sex (male), age (especially for men), BMI, and systolic and diastolic CBP were each 
associated with an increased likelihood of having masked hypertension; smoking status, 
Black race, and ethnicity were not. With the exception of smoking, these findings are 
consistent with Sheppard et al’s recent systematic review (see their Figure 2, p 622).31 
Controlling for CBP, the risk of having an elevated systolic aABP, elevated diastolic aABP, 
or masked hypertension, increases with age for men (OR>1.0), but decreases with age for 
women (OR<1.0). While the association with sex differs by age, men are at greater risk 
overall than women. There was also an independent association of BMI with the risk of 
elevated diastolic aABP only; Black race, Hispanic ethnicity, and smoking status were not 
significant independent predictors.
When we initiated the Masked Hypertension Study, we were concerned that one factor that 
might contribute to inflated estimates of the prevalence of masked hypertension and white-
coat hypertension (and the superiority of ABP over CBP for predicting outcomes) could be 
the poor reliability of the CBP measure, even when taken according to American Heart 
Association guidelines.32 Readings from a single visit, no matter how carefully taken, 
cannot adjust for the well-documented visit-to-visit variability in CBP.33 This is why we 
assessed CBP at 3 separate visits. Though not a central focus of the present analysis, the 
information in Table 3 and Supplemental Table 2 illustrates the increased reliability for CBP 
that results from averaging the 9 BP readings from 3 clinic visits, compared to the more 
typical 3 readings taken at a single visit. They show that the association of CBP with 
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demographic factors and BMI are more clearly revealed using the average of 3 visits rather 
than a single visit. Similarly, the correlations of CBP with mean awake ABP and mean sleep 
ABP are stronger for the 3-visit measure of CBP than for any of the single visit measures of 
CBP.
The Masked Hypertension Study has several strengths. In the absence of a nationally 
representative U.S. sample in which ABPM has been performed, this is one of the largest 
community samples with 24-hr ABPM in the United States. The sample was relatively 
healthy, with no evidence of overt CVD (myocardial infarction, stroke, congestive heart 
failure), no use of cardiovascular medications (except statins), and no use of blood pressure 
lowering agents. As such, this sample includes those individuals that primary care 
physicians are likely to see for well-patient visits, an occasion at which screening for 
hypertension is nearly universal. All participants had employer-provided health insurance, 
and therefore lack of access to care cannot account for the findings. Furthermore, CBP was 
assessed on 3 separate visits, with 3 research quality readings taken at each visit, and the 
average of all 9 readings provides a more reliable measure of CBP than readings from a 
single visit. However, the high quality of the CBP assessments limits the applicability of our 
findings, indeed those of almost all ABP studies, to the typical primary care setting. As 
others have repeatedly bemoaned,34, 35 the assessment of CBP in usual care is often 
seriously flawed, deviating procedurally from recommended guidelines. The extent to which 
our results might inform the difference between usual care clinic blood pressures and ABP is 
not known.
While the present findings contribute to a better understanding of the difference between 
CBP and aABP in generally healthy individuals, the study is not without limitations. First, 
the sample is not representative of the general population. Participants were all employed 
and had employer-provided health insurance. Second, the exclusion of non-employed 
individuals resulted in relatively few individuals over age 65, the group in which 
hypertension is most prevalent. While the sample is well suited to examine the CBP-aABP 
difference for individuals with non-elevated CBP, with only 5% of participants having 
elevated CBP (≥140/90 mmHg), it is less useful for examining the difference between CBP 
and ABP in the clinically important population of individuals with elevated CBP. This study 
is also unable to address the CBP-aABP difference among those taking an antihypertensive 
medication. The study did not perform home BP (HBP) monitoring, and therefore the 
findings may not be relevant to the CBP-HBP difference, or the prevalence and correlates of 
masked hypertension defined by HBP instead of aABP. Third, the exclusion of those with a 
screening BP ≥160/105 mmHg not taking medication may introduce a slight bias; however, 
only 25 of the 2591 screened individuals were excluded solely for this reason. The under-
representation of Blacks in the sample, is unfortunate. It is similarly unfortunate that 
minority (Black and Hispanic) participants were more likely to withdraw from the study 
prior to completing the 24-hour ABPM; importantly, attrition was not associated with blood 
pressure levels at either Visit 1 or Visit 2. Future population level research that includes 
ABPM – again as in the U.S. National Health and Nutrition Examination Survey 
(NHANES) – would address these issues. The present findings
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In contrast to previous large cohort studies of patients with elevated CBP and thus, to a 
widely held belief of clinicians, ABP is not usually lower than CBP in healthy employed 
individuals. Furthermore, a substantial number of otherwise healthy individuals have masked 
hypertension that may warrant treatment, or at least monitoring. Demonstrated CBP-aABP 
gradients if confirmed in studies with more diverse samples (e.g., NHANES) may provide 
guidance for primary care physicians as to when a given CBP indicates the need for ABPM 
to identify masked hypertension.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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- Contrary to common wisdom, we find that mean awake ambulatory blood 
pressure is typically higher than clinic blood pressure in CVD-free employed 
persons not being treated for hypertension; this difference is observed in 
males and females, Blacks and non-Blacks, Hispanics and non-Hispanics, 
and is especially pronounced in younger individuals and those with lower 
body mass index.
- Approximately 16% of those who have non-elevated BP in the clinic setting, 
averaged over 3 visits, have elevated average awake ambulatory BP, and 
therefore have masked hypertension.
What are the clinical implications?
- Among those individuals without a diagnosis of hypertension who are seen in 
a primary care setting, perhaps especially for a well-patient visit, physicians 
should probably be more concerned that the clinic BP underestimates, rather 
than overestimates, the patient’s average daytime BP.
- Given the substantial evidence that an elevated average awake blood pressure 
over the course of the day increases one’s risk for a cardiovascular event, 
regardless of one’s blood pressure in the clinic setting, it is likely that many 
adults, especially those with prehypertension in the clinic, would benefit from 
completing a 24-hour ambulatory blood pressure monitoring.
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Schematic of Masked Hypertension Study protocol
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CONSORT diagram for the Masked Hypertension Study: participant screening, recruitment, 
and attrition
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Distributions of clinic blood pressure, average awake ambulatory blood pressure, and the 
difference. Panels A and B show overlapping histograms for systolic and diastolic blood 
pressure, respectively. Panels C and D show the histograms for the clinic minus ambulatory 
blood pressure difference.
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LOESS estimates of the relationship of clinic blood pressure and average awake ambulatory 
blood pressure to age and BMI. Panel A shows the relationship of the two systolic blood 
pressure measures to age; Panel B shows the same relationship for the two diastolic blood 
pressure measures. Panel C shows the relationship of the two systolic blood pressure 
measures to BMI; Panel D shows the same relationship for the two diastolic blood pressure 
measures. The shaded areas identify the 95% confidence intervals.
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LOESS estimates of the likelihood of exceeding the ambulatory blood pressure threshold for 
hypertension in relationship to clinic blood pressure (mean of 3 visits). Panel A shows 
systolic blood pressure; Panel B shows diastolic blood pressure. The shaded areas identify 
the 95% confidence intervals. The analysis is restricted to the 841 participants who have 
non-elevated clinic blood pressure (systolic <140 mmHg and diastolic <90 mmHg).
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Table 1
Characteristics of Masked Hypertension Study Sample with Valid Awake ABP Data (N=888)
Measure N Mean (SD) or %
Age 888 45.0 (10.4)
    20–29 yrs 10.9%
    30–39 yrs 19.1%
    40–49 yrs 34.8%
    50–59 yrs 28.8%
    60–69 yrs 5.7%
    >=70 yrs 0.6%
Sex 888
    female 59.1%
    male 40.9%
Race 888
    Asian 4.8%
    Asian (Indian subcontinent) 4.4%
    Black 7.4%
    Native American 0.3%
    White 74.3%
    Other 8.1%
    Unknown 0.6%
Ethnicity 888
    non-Hispanic 88.0%
    Hispanic 12.0%
Years of Education 858 16.4 (3.0)
    12 yrs or less 7.9%
    13–15 yrs 25.6%
    16 yrs 28.3%
    >16 yrs 38.1%
Weight (lbs) 837 173.2 (40.0)
BMI (kg/m2) 837 27.6 (5.3)
    Normal (<25 kg/m2) 35.1%
    Overweight (25 – 30 kg/m2) 36.3%
    Obese (≥30 kg/m2) 28.6%
Smoking status 837
    Never smoked 67.4%
    Past smoker 25.0%
    Current smoker 7.6%
Diabetes (self-report) 837 3.6%
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Table 2
Distribution of difference between clinic BP* and mean awake ambulatory BP
Systolic BP Diastolic BP
Clinic BP higher than ABP 17.8% 35.8%
    Clinic BP higher by 5 mmHg or more 6.9% 14.2%
    Clinic BP higher by 10 mmHg or more 2.5% 4.2%
    Clinic BP higher by 15 mmHg or more 1.1% 0.9%
ABP higher than clinic BP 82.2% 64.2%
    ABP higher by 5 mmHg or more 63.7% 32.4%
    ABP higher by 10 mmHg or more 34.8% 9.2%
    ABP higher by 15 mmHg or more 14.4% 1.7%
*Clinic BP: the mean of 9 readings taken over 3 clinic visits
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